At the time of writing, BeiGene Ltd ADR [BGNE] stock is trading at $181.62, up 2.21%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BGNE shares have gain 1.43% over the last week, with a monthly amount drifted -4.67%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, JMP Securities started tracking the stock with Mkt Outperform rating on September 18, 2024, and set its price target to $288. Macquarie started tracking the stock assigning a Outperform rating and suggested a price target of $259 on September 12, 2023. Jefferies initiated its recommendation with a Buy and recommended $287 as its price target on August 17, 2023. Citigroup started tracking with a Buy rating for this stock on July 17, 2023, and assigned it a price target of $275. In a note dated June 30, 2023, Bernstein downgraded an Mkt Perform rating on this stock and revised its target price from $335 to $196.
For the past year, the stock price of BeiGene Ltd ADR fluctuated between $126.97 and $248.16. Currently, Wall Street analysts expect the stock to reach $267.33 within the next 12 months. BeiGene Ltd ADR [NASDAQ: BGNE] shares were valued at $181.62 at the most recent close of the market. An investor can expect a potential return of 47.19% based on the average BGNE price forecast.
Analyzing the BGNE fundamentals
According to BeiGene Ltd ADR [NASDAQ:BGNE], the company’s sales were 3.32B for trailing twelve months, which represents an 28.20% jump. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -0.26%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.95%. To continue investigating profitability, this company’s Return on Assets is posted at -0.54, Equity is -0.92 and Total Capital is -0.23. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.31.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 178.36 points at the first support level, and at 175.10 for the second support level. However, for the 1st resistance point, the stock is sitting at 183.60, and for the 2nd resistance point, it is at 185.59.
Ratios To Look Out For
It is important to note that BeiGene Ltd ADR [NASDAQ:BGNE] has a current ratio of 1.93. As well, the Quick Ratio is 1.72, while the Cash Ratio is 1.33. Considering the valuation of this stock, the price to sales ratio is 5.35, the price to book ratio is 5.64.
Transactions by insiders
Recent insider trading involved Wang Xiaodong, Chair, Scientific Advisory Brd, that happened on Dec 10 ’24 when 41760.0 shares were sold. Director, BAKER BROS. ADVISORS LP completed a deal on Dec 09 ’24 to sell 1.04 million shares. Meanwhile, Director XIAODONG WANG bought 41760.0 shares on Dec 10 ’24.
